hu05F442 Frozen Validation Report
342 PRS models · 1,636 protein predictions · 146 candidate variants. This static snapshot is generated from the public report JSON artifact.
Overview-first report: suggested next steps are shown before technical PRS and protein tables. Genetic evidence is not diagnostic by itself.
Clinical Variant Status
✓No confirmed pathogenic
Glucose and body-composition tendency
near-term focus
Inherited signals point to higher glucose and insulin-related tendency, with body-fat signals that do not all point in the same direction.
Full explanation
The clearest metabolic theme is glucose handling. Several genetic scores connected with type 2 diabetes, insulin biology, fasting proinsulin, and long-term blood sugar sit toward the high end.
Body-composition evidence is more nuanced. Arm fat, arm fat mass, weight, and hip size signals are elevated, while waist size and obesity signals are lower. That means this looks less like a simple whole-body obesity signal and more like a tendency where glucose regulation deserves attention even if body shape does not look high-risk.
Protein and variant evidence also points toward lipid, metabolic, and cellular cleanup pathways. These are not blood-test results, but they help explain why diet, training, and routine metabolic labs are more relevant than weight alone.
This category would be worth discussing if routine blood sugar, long-term blood sugar, fasting insulin, cholesterol, weight pattern, waist change, energy dips, excessive thirst, frequent urination, or strong family history makes it clinically relevant.
What to watch forPrioritize steady blood-sugar habits and review routine metabolic labs when they are due, especially if weight, waist, energy, or family-history context changes.
Show technical evidence
Risk-score evidence
- type 2 diabetes: risk percentile 97.6%, coverage 99%, PGS000125.
- fasting proinsulin: risk percentile 95.4%, coverage 95%, PGS000840.
- hba1c: risk percentile 94.6%, coverage 100%, PGS004003.
- incident type 2 diabetes: risk percentile 82.5%, coverage 99%, PGS002779.
- arm fat percentage: risk percentile 88.1%, coverage 97%, PGS003915.
- arm fat mass: risk percentile 82.7%, coverage 97%, PGS003916.
Protein pathway context
- LRPAP1: predicted level percentile 88.4%, R2 0.6658; pathway context only.
- MEP1B: predicted level percentile 88.1%, R2 0.6752; pathway context only.
- FUCA1: predicted level percentile 81.6%, R2 0.822; pathway context only.
Candidate variants
- Variant rs10402271 TT: snpedia_context.
- Variant rs10503669 CC: snpedia_context.
- Variant rs10105606 CC: snpedia_context.
- LOC107984063 rs10211524 GG: snpedia_context.
- Variant rs10089517 CC: snpedia_context.
Immune activation and autoimmune background
near-term focus
Immune and inflammatory signals are prominent, especially autoimmune and blood-cell traits, but allergy and some immune conditions trend lower.
Full explanation
The immune system is one of the strongest themes in the evidence. Several inherited signals connected with autoimmune conditions, inflammatory markers, lymphocyte percentage, basophil percentage, and connective-tissue involvement sit high.
The protein evidence supports this as a pathway-level finding. Several immune signaling and immune-cell surface proteins are at the tails, which makes the immune theme more convincing than a single score on its own.
The direction is mixed rather than uniformly high-risk. Some allergy-related, eosinophil, type 1 diabetes, and inflammatory bowel signals sit low, so the pattern is not simply a broad immune overactivity label.
This category would be worth reviewing if there are persistent joint swelling, unexplained rashes, unusual fatigue, recurrent inflammatory symptoms, abnormal inflammatory blood tests, new neurologic symptoms, or a close family history of autoimmune disease.
What to watch forTreat this as autoimmune and inflammation awareness; bring it up with a clinician if persistent inflammatory symptoms, abnormal labs, or strong family history are present.
Show technical evidence
Risk-score evidence
- multiple sclerosis: risk percentile 96.2%, coverage 100%, PGS001831.
- systemic lupus erythematosus: risk percentile 89.9%, coverage 99%, PGS000771.
- other systemic involvement of connective tissue: risk percentile 87.2%, coverage 86%, PGS000960.
- c reactive protein: risk percentile 94.1%, coverage 94%, PGS000314.
- lymphocyte percentage: risk percentile 99.3%, coverage 96%, PGS003941.
- basophil percentage: risk percentile 93.1%, coverage 96%, PGS003945.
Protein pathway context
- BST1: predicted level percentile 98.2%, R2 0.7006; pathway context only.
- MICB_MICA: predicted level percentile 96.3%, R2 0.7159; pathway context only.
- CSF2RB: predicted level percentile 96.2%, R2 0.6449; pathway context only.
- IFNGR2: predicted level percentile 81.4%, R2 0.6902; pathway context only.
- CFHR4: predicted level percentile 1.8%, R2 0.6355; pathway context only.
- IL1RAP: predicted level percentile 13.9%, R2 0.706; pathway context only.
Candidate variants
- IL10 rs1800896 CT: confirmation_required.
- CCL5 rs2280789 AG: confirmation_required.
- Variant rs11117432 GG: snpedia_context.
- Variant rs10276619 GG: snpedia_context.
- LOC105376219 rs10980800 TT: snpedia_context.
- SQRDL rs1044032 TT: snpedia_context.
Medication-response context
- CYP3A5: Poor Metabolizer, *3/*3; affected medicines include Tacrolimus, Sirolimus.
Mood, stress sensitivity, and reward context
near-term focus
Mood and stress-related inherited signals are high, while some addiction and trauma-context scores are lower.
Full explanation
Several mood-related genetic scores are high, including scores connected with depression, low mood, stress sensitivity, and neuroticism. This does not mean depression is present; it means this is a category where genetics gives a stronger-than-average background signal.
The reward and behavior context is mixed. Some scores connected with substance exposure are elevated, while alcohol use disorder and broader addiction-risk context are lower. That makes this more about stress sensitivity and exposure tendencies than a simple addiction-risk conclusion.
A nervous-system protein and medication-processing finding add context. The medication result is relevant only if medicines such as certain antidepressants are ever being considered by a clinician.
This category would be worth discussing if there are persistent low mood, anxiety, sleep disruption, loss of interest, major stress load, medication side effects, or close family history of mood disorders.
What to watch forUse this as a reason to take mood, sleep, stress load, and medication fit seriously if symptoms or treatment decisions ever arise.
Show technical evidence
Risk-score evidence
- lifetime major depressive disorder: risk percentile 98.9%, coverage 98%, PGS000139.
- neuroticism score: risk percentile 99.1%, coverage 100%, PGS001996.
- major depression: risk percentile 87.5%, coverage 98%, PGS000143.
- recent feelings of foreboding: risk percentile 91%, coverage 100%, PGS001920.
- feelings of worry or anxiety: risk percentile 16.2%, coverage 92%, PGS001021.
- post traumatic stress disorder: risk percentile 12.9%, coverage 100%, PGS005393.
Protein pathway context
- MDGA1: predicted level percentile 19.1%, R2 0.7077; pathway context only.
Candidate variants
- CACNA1C rs1006737 GG: snpedia_context.
Medication-response context
- CYP2C19: Rapid Metabolizer, *1/*17; affected medicines include Clopidogrel, Omeprazole, Pantoprazole, Citalopram, Escitalopram, Voriconazole.
Heart, lipids, and blood-pressure balance
useful to review
Coronary, LDL, ApoB, triglyceride, and blood-pressure signals are mostly favorable, but heart-structure and rhythm context still appears.
Full explanation
The cardiovascular pattern is one of the more protective parts of the report. Genetic scores connected with coronary disease, heart attack, chronic ischemic heart disease, LDL cholesterol, ApoB, triglycerides, and blood pressure are mostly favorable.
There are still counterweights. Heart-structure, rhythm, and family-history-related blood-pressure signals appear in the high tail, and lipid-related variants add extra context. This is why the category is balanced rather than simply reassuring.
Medication processing also matters here for a few specific medicines, including a blood thinner used after some heart events and common anti-inflammatory pain medicines. That is only relevant if those medicines are prescribed or being considered.
This category would be worth reviewing if blood pressure rises, cholesterol labs change, palpitations occur, chest symptoms appear, fainting happens, or there is a strong family history of early heart disease.
What to watch forKeep routine heart-risk basics current, and mention the medication-processing findings before starting heart-related or anti-inflammatory medicines.
Show technical evidence
Risk-score evidence
- coronary artery disease: risk percentile 3.7%, coverage 98%, PGS000058.
- myocardial infarction: risk percentile 2.8%, coverage 87%, PGS001316.
- chronic ischaemic heart disease: risk percentile 0.6%, coverage 88%, PGS000962.
- apolipoprotein b: risk percentile 7%, coverage 100%, PGS001889.
- high cholesterol: risk percentile 11.9%, coverage 90%, PGS000936.
- log triglycerides: risk percentile 15.3%, coverage 100%, PGS003801.
Protein pathway context
- APOBR: predicted level percentile 1.2%, R2 0.67; pathway context only.
- CFHR4: predicted level percentile 1.8%, R2 0.6355; pathway context only.
- LRPAP1: predicted level percentile 88.4%, R2 0.6658; pathway context only.
Candidate variants
- Variant rs10402271 TT: snpedia_context.
- Variant rs10503669 CC: snpedia_context.
- Variant rs10105606 CC: snpedia_context.
- C9orf3 rs10821415 CC: snpedia_context.
- LOC105377979 rs1015451 TT: snpedia_context.
- CDKN2B rs1063192 AG: confirmation_required.
Medication-response context
- CYP2C19: Rapid Metabolizer, *1/*17; affected medicines include Clopidogrel, Omeprazole, Pantoprazole, Citalopram, Escitalopram, Voriconazole.
- CYP2C9: Intermediate Metabolizer, *1/*3; affected medicines include Warfarin, Phenytoin, Celecoxib, Flurbiprofen, Losartan, Simvastatin.
Lung function and smoke sensitivity
useful to review
Lung-function signals are low, while asthma, rhinitis, nasal polyps, and lung-cancer signals are favorable.
Full explanation
Two lung-function scores are at the low end, which suggests this is a useful area for prevention and fitness attention. This does not say lung disease is present.
At the same time, several allergic-airway and lung-cancer signals are favorable, including asthma, rhinitis, nasal polyps, and lung cancer. That makes the respiratory pattern divergent rather than uniformly concerning.
A smoking-initiation signal is also present. Genetics cannot determine behavior, but this makes smoke and airway irritants especially important to avoid.
This category would be worth discussing if there is unexplained breathlessness, wheeze, chronic cough, reduced exercise tolerance, repeated chest infections, workplace exposure, or any smoking or vaping exposure.
What to watch forProtect lung capacity with regular aerobic training and strict smoke avoidance, and review symptoms if breathing or exercise tolerance changes.
Show technical evidence
Risk-score evidence
- lung function: risk percentile 98.5%, coverage 93%, PGS001237.
- forced expiratory volume in 1 second best measure: risk percentile 98.1%, coverage 100%, PGS001918.
- smoking initiation: risk percentile 81.1%, coverage 100%, PGS003747.
- asthma: risk percentile 4.3%, coverage 100%, PGS001849.
- hayfever allergic rhinitis: risk percentile 95.9%, coverage 87%, PGS001259.
- vasomotor and allergic rhinitis: risk percentile 2.3%, coverage 89%, PGS001109.
Protein pathway context
- KLK12: predicted level percentile 5.9%, R2 0.7889; pathway context only.
- MICB_MICA: predicted level percentile 96.3%, R2 0.7159; pathway context only.
- CSF2RB: predicted level percentile 96.2%, R2 0.6449; pathway context only.
- IFNGR2: predicted level percentile 81.4%, R2 0.6902; pathway context only.
Digestive tract, gallbladder, and liver pattern
useful to review
Digestive, bowel-tempo, gallbladder, and chronic liver signals cluster together, with some protective bowel-inflammatory context.
Full explanation
The digestive evidence is broad. Hemorrhoid, duodenal inflammation, duodenal ulcer, bowel-frequency, gallbladder inflammation, chronic nonalcoholic liver disease, and other intestinal-disease signals all appear toward the high end.
This does not mean any of those conditions are present. It does suggest that digestion, bowel pattern, reflux or ulcer-like symptoms, liver enzymes, and gallbladder-type symptoms are more relevant than average in this report.
Some protective signals also matter. Diverticular disease, abdominal pain, and ulcerative colitis signals are lower, so this should not be read as a general inflammatory bowel warning.
This category would be worth discussing if there is persistent abdominal pain, black stools, repeated reflux or ulcer symptoms, unusual bowel changes, right-upper-abdominal pain after meals, abnormal liver enzymes, or family history of bowel cancer.
What to watch forUse diet and routine care to support gut and liver health, and review persistent digestive, gallbladder-type, or liver-lab changes with a clinician.
Show technical evidence
Risk-score evidence
- hemorrhoid: risk percentile 99.8%, coverage 87%, PGS001024.
- duodenitis: risk percentile 95.9%, coverage 100%, PGS001852.
- duodenal ulcer: risk percentile 92.1%, coverage 79%, PGS001390.
- average number of times bowels opened per day: risk percentile 95.4%, coverage 85%, PGS001376.
- cholecystitis: risk percentile 89%, coverage 88%, PGS000942.
- other chronic nonalcoholic liver disease: risk percentile 88.6%, coverage 100%, PGS001860.
Protein pathway context
- MEP1B: predicted level percentile 88.1%, R2 0.6752; pathway context only.
- FUCA1: predicted level percentile 81.6%, R2 0.822; pathway context only.
- KLK1: predicted level percentile 88.3%, R2 0.6165; pathway context only.
Candidate variants
- Intergenic rs10795668 GG: snpedia_context.
- Variant rs11117432 GG: snpedia_context.
- MIR22,MIR22HG,WDR81 rs11078597 TT: snpedia_context.
- LOC107984063 rs10211524 GG: snpedia_context.
Medication-response context
- CYP2C9: Intermediate Metabolizer, *1/*3; affected medicines include Warfarin, Phenytoin, Celecoxib, Flurbiprofen, Losartan, Simvastatin.
Cancer-pattern awareness
useful to review
Cancer-related evidence is mixed: some colon, gynecologic, blood, and brain-context signals are elevated, while breast and lung signals are favorable.
Full explanation
Several cancer-context signals appear, including endometrial, lymphocytic leukemia, glioma, and benign colon-neoplasm scores. There is also variant evidence connected with colorectal and ovarian cancer research context.
The protective side is important. Breast cancer signals across several subtypes are low, lung cancer is low, and the general self-reported cancer score is low. This makes the category mixed rather than globally high.
Protein evidence points to growth-signaling and tissue-pathway context, not a measured cancer marker. None of this should be treated as a cancer diagnosis.
This category would be worth discussing in the context of age-appropriate screening, unusual bleeding, persistent unexplained symptoms, bowel changes, strong family history, or clinician concern about gynecologic, colon, blood, or neurologic symptoms.
What to watch forStay aligned with age-appropriate screening and use family history or persistent symptoms to decide whether any earlier discussion is warranted.
Show technical evidence
Risk-score evidence
- endometrial cancer: risk percentile 90.6%, coverage 97%, PGS002737.
- lymphocytic leukemia: risk percentile 91%, coverage 99%, PGS000077.
- benign neoplasm of colon: risk percentile 89.5%, coverage 100%, PGS001811.
- lung cancer: risk percentile 0.9%, coverage 87%, PGS001392.
- breast cancer: risk percentile 4.4%, coverage 90%, PGS000346.
- number of self reported cancers: risk percentile 18%, coverage 88%, PGS001005.
Protein pathway context
- PSCA: predicted level percentile 1.4%, R2 0.7849; pathway context only.
- FGFR4: predicted level percentile 1.7%, R2 0.6546; pathway context only.
- KLK1: predicted level percentile 88.3%, R2 0.6165; pathway context only.
- KLK12: predicted level percentile 5.9%, R2 0.7889; pathway context only.
- DKKL1: predicted level percentile 2.5%, R2 0.8321; pathway context only.
Candidate variants
- Intergenic rs10795668 GG: snpedia_context.
- LINC00824 rs10088218 GG: snpedia_context.
- CDKN2B rs1063192 AG: confirmation_required.
- Variant rs10484561 TT: snpedia_context.
Thyroid nodule background
background
Two inherited thyroid enlargement or nodule-related signals are high, without matching multi-lane support.
Full explanation
The thyroid finding is narrower than the metabolic and immune findings. Two genetic scores connected with non-toxic thyroid enlargement or nodules are high.
There is no strong matching protein or variant cluster in the provided evidence, so this should be treated as a focused awareness item rather than a broad endocrine conclusion.
This does not imply thyroid disease, abnormal thyroid hormone levels, or a thyroid nodule is present. It only says this category appeared strongly enough in one evidence lane to keep.
This category would be worth discussing if there is a neck lump, neck pressure, swallowing change, voice change, abnormal thyroid blood tests, previous thyroid imaging, or family history of thyroid disease.
What to watch forTreat this as thyroid-awareness context and review it only if symptoms, exam findings, thyroid labs, imaging, or family history make it relevant.
Show technical evidence
Risk-score evidence
- nontoxic multinodular goiter: risk percentile 96.3%, coverage 100%, PGS001814.
- other non toxic goitre: risk percentile 95.1%, coverage 91%, PGS000928.
Eye focusing and optic-nerve context
background
Myopia signal is high, while glaucoma, macular, and retinal-detachment signals are mostly favorable.
Full explanation
The clearest eye-related signal is myopia, meaning the inherited background leans toward near-sighted focusing traits. This is a trait-context finding, not a statement about current vision.
Several other eye signals are favorable, including glaucoma, primary open-angle glaucoma, macular degeneration, and retinal-detachment context. Variant evidence adds optic-nerve and myopia research context.
The practical interpretation is simple: the report points more toward focusing and routine eye-care relevance than toward broad retinal or glaucoma concern.
This category would be worth reviewing if vision changes, headaches with visual strain, high myopia, eye pressure concerns, family history of glaucoma, flashes or floaters, or retinal symptoms are present.
What to watch forKeep routine eye care current, especially if vision changes, high near-sightedness, eye-pressure concerns, or family history are relevant.
Show technical evidence
Risk-score evidence
- myopia diagnosis: risk percentile 97.6%, coverage 100%, PGS001994.
- glaucoma: risk percentile 4.8%, coverage 100%, PGS001836.
- primary open angle glaucoma: risk percentile 11.9%, coverage 87%, PGS002741.
- macular degenerationof retina nos: risk percentile 7.6%, coverage 100%, PGS001834.
- retinal detachments and defects: risk percentile 17%, coverage 100%, PGS001833.
- retinal disorders in diseases classified elsewhere: risk percentile 15.7%, coverage 80%, PGS001276.
Candidate variants
- Variant rs10089517 CC: snpedia_context.
- CDKN2B rs1063192 AG: confirmation_required.
Blood-cell trait and inflammation context
background
White-cell, red-cell, platelet, reticulocyte, and total-protein signals appear as a blood-trait cluster.
Full explanation
Several blood-trait signals appear together, including lymphocyte percentage, basophil percentage, red-cell distribution, platelet distribution, reticulocyte volume, and total protein. These are inherited trait tendencies, not blood-count results.
The direction is mixed. Some red-cell and platelet-count signals are lower, while distribution and immune-cell percentage signals are higher. Protein and variant evidence supports blood-cell and immune-cell context.
This category overlaps with immune findings but is kept separate because it may matter when interpreting routine blood tests.
This category would be worth discussing if routine blood counts are repeatedly abnormal, there is unexplained bruising, persistent fatigue, recurrent infections, unusual clotting or bleeding symptoms, or clinician concern about inflammatory blood markers.
What to watch forUse this as context for routine blood counts; act on real lab abnormalities or symptoms rather than genetics alone.
Show technical evidence
Risk-score evidence
- lymphocyte percentage: risk percentile 99.3%, coverage 96%, PGS003941.
- basophil percentage: risk percentile 93.1%, coverage 96%, PGS003945.
- red blood celldistribution width: risk percentile 93.9%, coverage 100%, PGS001908.
- platelet distribution width: risk percentile 85.3%, coverage 100%, PGS001972.
- mean reticulocyte volume: risk percentile 81.4%, coverage 100%, PGS002003.
- total protein: risk percentile 81.5%, coverage 100%, PGS002001.
Protein pathway context
- APOBR: predicted level percentile 1.2%, R2 0.67; pathway context only.
- CSF2RB: predicted level percentile 96.2%, R2 0.6449; pathway context only.
- BST1: predicted level percentile 98.2%, R2 0.7006; pathway context only.
- CFHR4: predicted level percentile 1.8%, R2 0.6355; pathway context only.
Candidate variants
- RCL1 rs10758658 GG: snpedia_context.
- LOC105376219 rs10980800 TT: snpedia_context.
- ATP2B4 rs10900585 TT: snpedia_context.
Skin, allergy, and tissue-barrier pattern
background
Eczema or dermatitis signal is elevated, but asthma, rhinitis, psoriasis, and broader atopy signals are mostly favorable.
Full explanation
The skin and allergy pattern is mixed. Eczema or dermatitis sits high, while asthma, rhinitis, psoriasis, general atopic disease, nasal polyps, and hair-follicle signals are mostly favorable.
Protein evidence adds barrier and immune-pathway context. That supports keeping this as a skin and tissue-barrier theme rather than treating it as a broad allergy-risk theme.
Because several allergy traits are protective, this should not be read as high general allergy burden. It is more specific to skin-barrier and dermatitis-type awareness.
This category would be worth discussing if there are persistent rashes, recurrent eczema flares, skin infections, severe itching, occupational exposures, or treatment-resistant skin symptoms.
What to watch forUse skin-barrier care and irritant awareness if symptoms occur, but do not assume broad allergy risk from this pattern.
Show technical evidence
Risk-score evidence
- eczema dermatitis: risk percentile 88.8%, coverage 87%, PGS000944.
- hayfever allergic rhinitis: risk percentile 95.9%, coverage 87%, PGS001259.
- vasomotor and allergic rhinitis: risk percentile 2.3%, coverage 89%, PGS001109.
- asthma: risk percentile 4.3%, coverage 100%, PGS001849.
- psoriasis: risk percentile 3.3%, coverage 90%, PGS001313.
- diseases of hair and hair follicles: risk percentile 8.4%, coverage 100%, PGS001873.
Protein pathway context
- KLK12: predicted level percentile 5.9%, R2 0.7889; pathway context only.
- IL1RAP: predicted level percentile 13.9%, R2 0.706; pathway context only.
- FOLR3: predicted level percentile 18%, R2 0.9226; pathway context only.
- MICB_MICA: predicted level percentile 96.3%, R2 0.7159; pathway context only.
Candidate variants
- IL10 rs1800896 CT: confirmation_required.
- CCL5 rs2280789 AG: confirmation_required.
Joint, fascia, and uric-acid load
background
Fascia, gout, ankle-spacing, and connective-tissue signals appear, while some injury and falls signals are favorable.
Full explanation
This is a musculoskeletal and load-management theme. Genetic signals connected with palmar fascia contracture, gout, ankle spacing, and connective-tissue involvement appear elevated.
Protective signals are also present for knee derangement, bunion tendency, and falls. That makes this less about fragility and more about tissue load, joint mechanics, and inflammatory flare context.
The evidence also overlaps with body-frame and training. The practical value is in choosing progressive loading, mobility, and recovery habits that keep joints and tendons tolerant.
This category would be worth discussing if there are recurrent tendon problems, hand contracture, gout-like flares, swollen joints, persistent foot or ankle pain, or a strong family history of gout or connective-tissue disease.
What to watch forBuild strength progressively, keep joint loading consistent, and review gout-like flares or persistent tendon or hand-fascia symptoms if they occur.
Show technical evidence
Risk-score evidence
- contracture of palmar fascia dupuytren s disease: risk percentile 83.9%, coverage 100%, PGS001880.
- gout: risk percentile 82.8%, coverage 83%, PGS001249.
- ankle spacing width: risk percentile 90.6%, coverage 93%, PGS001241.
- other systemic involvement of connective tissue: risk percentile 87.2%, coverage 86%, PGS000960.
- internal derangement of knee: risk percentile 18%, coverage 83%, PGS001027.
- hallux valgus: risk percentile 9.1%, coverage 100%, PGS001881.
Protein pathway context
- KLK1: predicted level percentile 88.3%, R2 0.6165; pathway context only.
- CFHR4: predicted level percentile 1.8%, R2 0.6355; pathway context only.
Candidate variants
- Variant rs11177669 GG: snpedia_context.
- SUPT3H rs10948222 TT: snpedia_context.
- ZNF483 rs10980926 GG: snpedia_context.
- ZNF483 rs10441737 TT: snpedia_context.
Brain-imaging background
background
Several brain-region and white-matter signals are interesting research context, not diagnosis or medical-risk proof.
Full explanation
The evidence includes brain-region and white-matter research scores. These can be interesting for understanding nervous-system background, but they should not be used as diagnostic findings.
Some of these rows point high and others point low across different brain regions. A nervous-system protein and one variant add background context, but this still remains a research-context category.
The strongest practical connection is with the separate mood and stress-sensitivity theme, not with any claim about a neurological disorder.
This category would be worth discussing only if there are real-world neurological changes, cognitive changes, new headaches with concerning features, movement symptoms, seizures, or clinician-directed imaging questions.
What to watch forTreat this as background only; use real symptoms or clinician findings, not genetics alone, to decide whether neurological review is relevant.
Show technical evidence
Risk-score evidence
- volume of grey matter in superior frontal gyrus: risk percentile 99.5%, coverage 89%, PGS001597.
- volume of caudate: risk percentile 91.9%, coverage 89%, PGS001543.
- volume of hippocampus: risk percentile 10.1%, coverage 88%, PGS001630.
- volume of accumbens: risk percentile 15.4%, coverage 86%, PGS001538.
- total volume of white matter hyperintensities: risk percentile 84.4%, coverage 88%, PGS001534.
- median t2star in putamen: risk percentile 80.6%, coverage 90%, PGS001512.
Protein pathway context
- MDGA1: predicted level percentile 19.1%, R2 0.7077; pathway context only.
Candidate variants
- Variant rs10276619 GG: snpedia_context.
Medication Safety
Genes below have pharmacogenomic phenotypes that may affect drug choice or dose review. Use this as a clinical discussion aid, not as a standalone prescribing instruction.
CYP2C19
RAPID METABOLIZER
*1/*17
Affected drugs: Clopidogrel, Omeprazole, Pantoprazole, Citalopram, Escitalopram, Voriconazole
CYP2C9
INTERMEDIATE METABOLIZER
*1/*3
Affected drugs: Warfarin, Phenytoin, Celecoxib, Flurbiprofen, Losartan, Simvastatin
CYP3A5
POOR METABOLIZER
*3/*3
Affected drugs: Tacrolimus, Sirolimus
UGT1A1
INDETERMINATE
*1/*80
Affected drugs: Irinotecan, Atazanavir
CYP2B6
POOR METABOLIZER
*9/*9
Affected drugs: Efavirenz, Bupropion, Methadone
This report comes from consumer microarray data with statistical imputation. Confirm clinically before changing prescriptions.